Bicycle therapeutics announces two abstracts accepted for presentation at the 2024 asco annual meeting

Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced the acceptance of two abstracts for poster presentation at the 2024 american society for clinical oncology (asco) annual meeting, taking place may 31-june 4 in chicago. poster presentation details: title: breaking from the paradigm of antibody-d.
BCYC Ratings Summary
BCYC Quant Ranking